Gilead Sets Remdesivir Price, Commits Nearly All Near-Term Supplies To US
Executive Summary
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.
You may also be interested in...
Coronavirus Update: Gilead's Veklury Gets Full FDA Approval, Roche Partners With Atea
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.
Lilly’s EUA Timeline For COVID-19 Combo Antibody Depends On Safety Data, Manufacturing
Single neutralizing antibody moves to US FDA with data showing reduced hospitalization, while Lilly’s EUA filing for two-antibody combo awaits safety data and more certainty about production capabilities.
Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.